entertainment -WSS

entertainment

author：entertainment 2025-08-25 06:01:14 - browse：7

a stethoscope and money – hospitals and health insurance coverage from STAT — Bright Health is officially leaving the health insurance market. The company has agreed to sell its Medicare Advantage plans to Molina Healthcare. Adobe

Bright Health Group has agreed to sell its Medicare Advantage plans to its publicly traded peer Molina Healthcare.

Regulators must approve the deal. But the pending sale of its Medicare Advantage business means the financially distressed Bright has exited the health insurance market that the company was founded on. It will solely operate roughly 70 physician clinics located in California, Texas, and Florida.

Molina agreed to pay $600 million for Bright’s 125,000 California Medicare Advantage enrollees, which equates to about $4,800 for each person. The federal government paid insurance companies almost $12,000, on average, for each MA enrollee in 2022. Molina said in a news release that Bright’s current book of business generates $1.8 billion of revenue, or more than $14,000 for each member.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

WSS

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Fatty liver disease was alleviated by Lilly’s ‘triple

CDC director unscathed in first congressional testimony

Flagship Pioneering launches a new biotech in two countries

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

FDA investigates CAR

entertainment

entertainment

hotspot

What does generative AI mean for health care? We asked experts

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Dobbs anniversary: the lost opportunity of abortion as health care

Pediatric cancer treatments threatened by a new FDA policy

Supreme Court strikes down use of affirmative action

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Drug repurposing or repositioning? The language matters

Diagnostic tests are hitting their mathematical limits

Novavax promises a turnaround & Lilly roils the obesity market

Organ aging and disease risk measured by new blood test

knowledge

CDC director unscathed in first congressional testimony

ReNAgade cuts staff seven months after raising $300 million

As biotech industry slumps, bioscience job market is upside down

Vertex cell therapy lets patients with type 1 diabetes stop insulin

How to pay for weight loss drugs and save Medicare

What affirmative action's end means to a medical student

leisure time

hotspot

hotspot

focus